5020

Sim & McBurney

Patent and Trade-mark Agents

330 University Avenue
6th floor
Toronto, Canada
M5G 1R7

Telephone (416) 595-1155
Fax (416) 595-1163

Please Quote
Our ref. 1038-1183 MIS/ac

Your ref.

Writer's Ext. 239

E-mail: **mistewart@sim-mcburney.com**

November 9, 2001

VIA COURIER

The Commissioner of Patents
and Trademarks
Washington, D.C. 20231
United States of America

Dear Sirs:

RE: U.S. Patent Application No. 09/914,622
Filed: February 2, 2000
Applicant: Sheena M. Loosmore
Title: MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY HAEMPHILUS INFLUENZAE

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/914,622. The items indicated by asterisks will follow shortly.

Respectfully submitted,

Michael I. Stewart
Registration No. 24,973

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1183 MIS:ac	SERIAL NO. 09/914,622
	APPLICANT Sheena M. Loosmore	
	FILING DATE February 2, 2000	GROUP ---

OIPE JC139 NOV 13 2001 PATENT & TRADEMARK OFFICE

RECEIVED JAN 14 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
		5,869,302	Feb. 19, 1999	Loosmore et al.			
		4,496,538	Jan. 29, 1985	Gordon			
		5,603,938	Feb. 18, 1997	Barenkamp			
		5,646,259	July 8, 1997	St. Geme, III et al.			
		5,506,139	Apr. 9, 1996	Loosmore et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION YES	TRANSLATION NO
		WO 00/35477	June 22, 2000	PCT				
		WO 94/21290	Sept. 29, 1994	PCT				
		WO 94/00149	Jan. 6, 1994	PCT				
		WO 95/34308	Dec. 21, 1995	PCT				
		WO 97/36914	Oct. 9, 1997	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1. Barbour, M.L. R.T. Mayon-White, C. Cole, D.W.M. Crook, and E.R. Moxon. 1995. The Impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J. Infect. Dis. 171:93-98.
		2. Berkowitz et al. 1987. J. Pediatr. 110:509.
		3. Claesson et al. 1989. J. Pediatr. 114:97.
		4. Black, S.B., H.R. Shinefield, B. Fireman, R. Hiatt, M. Polen, E. Vittinghoff, The Northern California Kaiser Permanent Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate *Haemophilus* influenzae type b (HbOC) vaccine in a United States population of 61,080 children. 1991. Pediatr. Infect. Dis. J. 10:97-104.
		5. Nitta, D.M., M.A. Jackson, V.F. Burrry and L.C. Olson. 1995. Invasive Haemophilus influenzae type F disease. Pediatr. Infect. Dis J. 14:157-160.
		6. Waggoner-Fountain, L.A. et al. The emergence of Haemophilus influenzae types e and t as significant pathogens. Clin. Infect. Dis. 21:1 122-1324.
		7. Madore, D.V. 1996. Impact of immunization on *Haemophilus influenzae* type b disease. Infectious Agents and Disease **5**:8-20.
		8. Bluestone, C.D. 1982. Current concepts in otolaryngology. Otitis media in children: to treat or not to treat? N. Engl. J. Med. **306**:1399-1404.

EXAMINER:	DATE CONSIDERED:

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.**

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 1038-1183 MIS:ac	SERIAL NO. 09/914,622
	APPLICANT Sheena M. Loosmore	
	FILING DATE February 2, 2000	GROUP ---

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
		9. St. Geme III W.J. et al., Infection and Immunity (1998), p. 364-368.
		10. St. Geme III, J.W., S. Falkow, and S.J. Barenkamp. 1993. High-molecular-weight proteins of nontypeable *Haemophilus influenzae* mediate attachment to human epithelial cells. Proc. Natl. Acad. Sci. USA **90:** 2875-2879.
		11. Barenkamp, S.J. 1996. Immunization with high-molecular-weight adhesion proteins of nontypeable *Haemophilus influenzae* modifies experimental otitis media in chinchillas. Infect Immun. **64:** 1246-1251.
		12. Yang, Y.-P., S.M. Loosmore, B. Underdown, and M.H. Klein. 1998. Nasopharyngeal colonization with nontypeable *H. influenzae* in chinchillas. Infect. Immun. **66:**1973-1980.
	*	13. St. Geme, J.W. and d. Cutter. 1995. Evidence that surface fibrils expressed by haemophilus influenzae type b promote attahment to human epithelial cells. Molec. Microbiol. 15:77-85.
		14. Retzlaff, C., et al. 1994 Bacterial heat shock proteins directly induce cytokine MRNA and interleukin-1 secretion in macrophage cultures. Infect. Immun. 62: 5689-5693.
		15. Loosmore, S.M. et al. 1998. The Haemophilus influenzae HtrA protein is a protective antigen. Infect. Immun. 66: 899-906.
		16. Holmes, D.S. and Quigley, M. 1981. A rapid boiling method for the preparation of bacterial plasmids. Anal. Biochem. 114:193-197.
		17. Barenkamp, S.J., and E. Leininger. 1992. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable *Haemophilus influenzae* high-molecular-weight surface-exposed proteins related to filamentous hemaglutinin of *Bordetella pertussis*. Infect. Immun. **60:**1302-1313
		18. Barenkamp, S.J., and F.F. Bodor. 1990. Development of serum bactericidal activity following nontypable *Haemophilus influenzae* acute otitis media. Pediatr. Infect. Dis. **9:**333-339.
		19. Barenkamp S.J., and St. Geme III J. Molecular Microbiology (1996), 1215-1223.
		20. Barenkamp S.J., and J.W. St. Geme III. 1994. Genes encoding highmolecular wieght adhesion proteins of nontypeable Haemophilus Influenzae are part of gene clusters. Infect. Immun. 62: 3320-3328
	*	21. St. Geme J.W., D. Cutter, and S.J. Barenkamp. 1996. Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. J. Bact. 178:6281-6287.
		22. Tabor, s., and C.C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. USA 82: 1074-1078.

EXAMINER:	DATE CONSIDERED:

***EXAMINER: Initial if referenc c nsid red, whether r not citation is in c nformance with MPEP 609; Draw line through citati n if in conformanc and not considered. Include copy of this form with next communication with applicant.**
*** Will follow shortly**